Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence contained within the company's submission to NICE. The evidence, which included a randomised controlled trial (RCT) of degarelix versus leuprorelin, found that degarelix was noninferior to leuprorelin for reduction of testosterone levels and that degarelix achieved a more rapid suppression of prostate-specific antigen levels and subsequently decreased incidences of testosterone flare associated with luteinising hormone releasing-hormone (LHRH) agonists. However, protection against testosterone flare for the comparators in the clinical trials was not employed in line with UK clinical practice. Further claims surrounding overall survival, cardiovascular adverse events and clinical equivalence of the comparator drugs from six RCTs of degarelix should be regarded with caution because of flaws and inconsistencies in the pooling of trial data to draw conclusions. The costeffectiveness evidence included a de novo economic model. Based on the ERG's preferred base case, the deterministic incremental cost-effectiveness analysis (ICER) for degarelix versus 3-monthly triptorelin was £14,798 per quality-adjusted life-year (QALY) gained. Additional scenario analyses undertaken by the ERG resulted in ICERs for degarelix versus 3-monthly triptorelin ranging from £17,067 to £35,589 per QALY gained. Subgroup analyses undertaken using the Appraisal Committee's preferred assumptions suggested that degarelix was not cost effective for the subgroup with metastatic disease but could be cost effective for the subgroup with spinal metastases. The company submitted further evidence to NICE following an initial negative Appraisal Committee decision. Further analyses from the Decision Support Unit found that that, whilst some evidence indicated that degarelix could be cost effective for a small subgroup of people with spinal cord compression (SCC), data on the potential size of this subgroup and the rate of SCC were insufficient to estimate an ICER based on the evidence submitted by the company and a separately commissioned systematic review. NICE recommended degarelix as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the UK NHS in June 2016.
Introduction
Health technologies must be shown to be clinically effective and to represent a cost-effective use of UK NHS resources to be recommended for use within the NHS in England. The National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health in priority areas with significant impact. The NICE Single Technology Appraisal (STA) process usually covers new technologies soon after UK market authorisation and is specifically designed for the appraisal of a single health technology within a single indication [1] . Within the STA process, the manufacturer provides NICE with a written submission, alongside a mathematical model, that summarises the company's estimates of the clinical and cost effectiveness of the technology. This submission is reviewed by an external academic organisation independent of NICE-the Evidence Review Group (ERG)-that consults with clinical specialists and produces a report. The NICE Appraisal Committee considers the company's submission (CS), the ERG report and testimony from experts and other stakeholders then formulates preliminary guidance in the form of an Appraisal Consultation Document (ACD), which indicates the committee's initial recommendations on the use of the technology. Stakeholders are then invited to comment on the submitted evidence and the ACD, after which either a subsequent ACD is produced or a Final Appraisal Determination (FAD) is issued, which is open to appeal. When a technology is recommended without restriction, the FAD is produced without the ACD step. This paper presents a summary of the ERG report [2] for the STA of degarelix for the treatment of advanced hormone-dependent prostate cancer and the subsequent development of NICE guidance for the use of this drug in England. Full details of all relevant appraisal documents (including the appraisal scope, ERG report, company and consultee submissions, FAD and comments from consultees) can be found on the NICE website [3] .
The Decision Problem
Prostate cancer is the most common cancer in men in the UK [4] . In 2014, the incidence of prostate cancer in England was 39,741 men and was highest in older men, with the peak in absolute numbers between the ages of 65 and 84 years [5] . More than 10,000 prostate cancer-related deaths occur each year in the UK. As well as age, other risk factors include Black ethnic origin and a family history of prostate cancer in a close male relative [5, 6] . Prostate cancer may remain localised and develop slowly over many years from small tumours of cancer within the prostate gland. If the cancer spreads to tissues surrounding the prostate, such as the bladder and regional lymph nodes, the cancer is considered locally advanced. Prostate cancer is considered to be metastatic when it spreads beyond the prostate gland to other areas of the body such as the bones [7] .
Early, or localised, prostate cancer is unlikely to produce many symptoms. The symptoms of advanced prostate cancer occur when the prostate gland becomes enlarged and results in urinary tract problems and pain or blood when passing urine. Prostate-specific antigen (PSA) protein levels, which can be measured from blood samples, are higher in men with advanced prostate cancer than in those with a healthy prostate.
Current Treatment
Surgery, including prostatectomy or castration (orchidectomy) and/or radiotherapy may be offered to some men to treat early prostate cancer. However, androgen-derivation therapy is the mainstay of treatment for men with advanced prostate cancer who are not eligible for surgery or who prefer the medical approach to castration over surgery. Androgen-deprivation therapy, or androgen withdrawal, involves using either an agonist of luteinising hormonereleasing hormone (LHRH) or an antagonist of gonadotrophin-releasing hormone (GnRH) to reduce the release of the luteinising hormone (LH) and follicle-stimulating hormone (FSH) and subsequently the testosterone secreted by the testes to castrate levels. LHRH agonists used to treat prostate cancer include goserelin, leuprorelin and triptorelin in combination with anti-androgen testosterone flare protection. Some prostate cancer is also managed using anti-androgen drug monotherapy.
Degarelix (Firmagon Ò ) is a selective GnRH antagonist that competitively and reversibly binds to pituitary GnRH receptors, leading to a rapid reduction in the release of the gonadotrophins LH and FSH. A decrease in LH and FSH levels results in a rapid reduction to castrate levels of testosterone secretion by the testes. Degarelix holds a European marketing authorisation for the treatment of adult male patients with advanced hormone-dependent prostate cancer. Degarelix is the first GnRH agonist to receive a licensed indication for the treatment of advanced hormone-dependent prostate cancer in adult males in the UK. As a GnRH antagonist, it possesses a different mode of action to the LHRH agonist comparators that are also licensed for this indication.
In July 2013, NICE issued a final scope to appraise the clinical and cost effectiveness of degarelix within its licensed indication for the treatment of locally advanced hormone-dependent prostate cancer in men. In August 2013, the company (Ferring Pharmaceuticals) provided a submission to NICE relating to the clinical and cost effectiveness of degarelix for the treatment of locally advanced hormone-dependent prostate cancer in men.
The Independent Evidence Group (ERG) Review
The ERG report comprised a critical review of the clinical and cost-effectiveness evidence presented in the CS, an assessment of the appropriateness of the company's analysis and an interpretation of the evidence. The ERG sought clarification on specific points in the CS, and the company provided additional information. The ERG also modified the company's decision analytic model to examine the impact of altering some of the key assumptions.
Clinical Evidence Provided by the Company
The clinical-effectiveness evidence in the CS was based predominantly on six randomised controlled trials (RCTs): two trials of degarelix versus leuprorelin (CS21 [8] and CS37) and four trials of degarelix versus goserelin (CS28 [9] , CS30 [10] , CS31 [11] and CS35), ranging in duration from 3 to 14 months. Four of the trials used the licensed dose of degarelix (two initial subcutaneous injections of 120 mg each for a total of 240 mg for 1 month followed by monthly maintenance doses of 80 mg); whereas two trials used unlicensed 3-or 6-monthly dose schedules, which limited the relevance of these two trials to the decision problem. The sample size in the RCTs ranged from 42 to 859 patients. The main pivotal trial of degarelix (CS21) had a primary endpoint of probability of testosterone levels B0.5 ng/ml from day 28 to day 84. Pooled analyses using different combinations of the six RCTs were presented for testosterone response, PSA progression-free survival (PFS), serum alkaline phosphatase and adverse events (AEs). The CS included pairwise meta-analyses performed for the following outcomes: reduction in prostate size, change in international prostate symptom score (IPSS), change in PSA from baseline, and overall survival (OS). The company conducted a network meta-analysis (NMA) for degarelix, goserelin, leuprorelin, triptorelin and bicalutamide. The CS stated that, because usable data on other outcomes were lacking, the NMA was restricted to the OS outcome. Trial CS21 showed that degarelix (240 mg/80 mg) was non-inferior to monthly leuprorelin (7.5 mg) for the primary endpoint of probability of testosterone levels B0.5 ng/ml from day 28 to day 364. Additionally, degarelix achieved a more rapid suppression of PSA levels (median reduction at day 28), which decreases the incidence of testosterone flare associated with LHRH agonists, than did leuprorelin (p \ 0.0001) in trial CS21. The pairwise meta-analysis of mortality favoured degarelix; however, the result only became statistically significant (p = 0.045) when results from the CS35 trial, which used an unlicensed 3-monthly dose of degarelix, were included. No statistically significant differences were found for OS in the NMA; however, the forest plot showed that leuprorelin and goserelin were associated with increased mortality compared with degarelix, whereas mortality appeared to be lower for triptorelin than for degarelix.
Critique of Clinical Evidence and Interpretation
The ERG considered the included trials to be generally of good methodological quality but that the two trials using unlicensed doses of degarelix were not fully applicable to the decision problem.
The target population was adult men with advanced hormone-dependent prostate cancer, including both locally advanced and metastatic disease. The study populations for the included trials generally had lower PSA levels and consequently less advanced cancer than the licensed population expected in clinical practice in England. The pivotal trial CS21 was powered to show non-inferiority for the primary endpoint of reduction of testosterone to castrate level in those with all stages of prostate cancer requiring androgen-deprivation therapy. The trial was not powered to make substantive conclusions about the target population as the trial population included patients with other classifications, including 'localised' and 'not classifiable' prostate cancer. The number of patients in trial CS21 who were reported to have locally advanced or metastatic disease and therefore considered relevant to the decision problem was 303 of 607 patients (49% of the trial population). However, clinical advice provided to the ERG by three consultant urologists practicing across the UK suggested this would have limited effect on the assessment of efficacy given that severity was balanced between the intervention and control arms across trials.
The NICE scope specified that the comparator LHRH agonists should be used in combination with short-term anti-androgen treatment (such as bicalutamide or cyproterone acetate) to prevent testosterone flare associated with the early stages of treatment with LHRH agonists. The use of testosterone flare protection was inconsistent for patients in the comparator arms, with two trials providing flare protection at a much lower level than would be expected in current clinical practice in England.
The NICE scope specified bicalutamide monotherapy as a relevant comparator to degarelix. The CS excluded bicalutamide monotherapy on the basis of insufficient evidence to inform a robust NMA. Clinical advice received by the ERG suggested that, whilst bicalutamide monotherapy may be a preferred treatment option for some patients, particularly those with locally advanced disease and younger patients in whom maintenance of sexual function is preferable, it is used in a relatively small proportion of patients.
The CS contained simple pooled analyses of selections of the different trials for testosterone response: PSA, PFS, serum alkaline phosphatase, and AEs. The ERG noted that these should be interpreted with caution as data were not formally meta-analysed, and simple pooling assumes no difference between individual studies and may yield counterintuitive or spurious results. The company presented a post hoc pooled analysis of cardiovascular serious AEs (SAEs) from the six included trials. These indicated men with a history of cardiovascular disease (CVD) experienced a significantly lower risk of CVD AEs if treated with degarelix compared with an LHRH agonist.
However, CVD SAEs were not a pre-defined clinical endpoint but instead were AEs that were collected post hoc, and no effect has been demonstrated in men without pre-existing CVD. Clinical advice received by the ERG suggested that evidence for a link between LHRH agonists and CVD is correlative, and prospective evidence on which to base conclusions about a potential relationship between these treatments and the cardiovascular risk is lacking. The ERG noted that the company attempted to assign causal conclusions without direct evidence to corroborate the assumptions.
The results of the company's meta-analyses should also be interpreted with caution. On the basis of the NMA and a paper [12] and poster [13] that did not include one of the comparators (triptorelin), the company assumed that the efficacy and safety profiles of the LHRH agonist comparators were equivalent. The ERG considered the assumption that the LHRH agonists goserelin, leuprorelin and triptorelin are clinically equivalent to be unproven and therefore inappropriate. The IPSS questionnaire and prostate size outcomes only considered degarelix compared with goserelin; therefore, the conclusion stated by the company about degarelix versus LHRH agonists is too broad. Similarly, the company's meta-analyses of OS and PSA response only considered degarelix compared with leuprorelin or goserelin, and therefore could not draw conclusions about all LHRH agonists.
The NMA used data from trials that were too short in duration to enable meaningful conclusions about OS in this population. The absolute number of deaths in the included trials was small (41 of 2328 patients), and clinical advice received by the ERG suggested that comparative data relating to 1-year survival should be treated with caution and that trials of this size and duration are not sufficient to capture meaningful differences in survival in this stage of disease. Clinical advice also suggested that at least 5-year follow-up would be required to gather appropriate numbers of events (deaths).
The CS presented a meta-analysis of AEs from the four RCTs (CS21, CS28, CS30, CS31) and concluded that overall, no statistically significant difference in the proportion of patients experiencing any AEs, death or SAEs was observed between the degarelix 240 mg/ 80 mg group and the LHRH agonist group. The ERG considered the frequency and nature of AEs for degarelix reported in the CS to be similar to levels seen in trials of goserelin, leuprorelin and triptorelin. Common long-term AEs included impact on bone health, lower metabolism, cardiovascular risk, sexual dysfunction, gynecomastia, reduction in penile and testicular size, fatigue, hot flashes, anaemia, and potential cognitive decline.
Cost-Effectiveness Evidence Provided by the Company
The CS presented a systematic review of cost-effectiveness studies that included three relevant studies. The review concluded the studies were inadequate to fully inform decision making in the UK context, hence a de novo model was required. The CS included a de novo Markov treatment-sequence model to estimate the costs and benefits of degarelix versus goserelin 10.8 mg (Zoladex Ò Transitions from first-line treatment were based on data for PSA progression with degarelix and LHRH agonists. The model assumed that the efficacy of each of the LHRH agonists (goserelin, leuprorelin and triptorelin) was equivalent. The model used data from the CS21 and CS21A trials, which compared degarelix versus leuprorelin for a period of 1 year before crossover to degarelix was allowed for all patients. A hazard ratio (HR) for PSA progression of 1.71 (1.74) for leuprorelin compared with degarelix for the intention-to-treat (ITT) population (PSA [20 ng/ml population) was estimated from the CS21 and CS21A trial data. PSA progression for degarelix was modelled using a log normal distribution. The HRs were applied to the parametric curves assuming proportional hazards. Two scenario analyses were also presented: (1) a scenario in which the efficacy of degarelix and LHRH agonists was assumed to be equal and (2) a scenario in which the efficacy of degarelix and LHRH agonists was assumed to be equal after 1 year.
Duration of response to subsequent lines of treatment was based on estimated response durations reported in the European Association of Urology (EAU) guidelines [14] . Mortality rates that were age specific and dependent on the presence of metastatic disease were derived from data from the Office for National Statistics (ONS) [15] and Scottish prostate cancer mortality data. Mortality for patients receiving first-line treatment was calculated based on the proportions of patients with locally advanced and metastatic disease from trial CS21. Patients receiving chemotherapy, abiraterone or supportive/palliative care were assumed to have metastatic disease, so the model applied a metastatic disease mortality rate for these patients. However, it applied a different mortality rate for patients receiving abiraterone. An increased hazard of mortality was applied for patients with metastatic disease once they had progressed from first-line treatment.
The company's base-case comparison of degarelix versus 3-monthly goserelin suggested degarelix produced cost savings of £1697 per patient and a quality-adjusted life-year (QALY) gain of 0.58, hence degarelix was expected to dominate goserelin. The estimated cost savings were due to a reduction in subsequent-line therapies and cardiovascular/musculoskeletal events compared with LHRH agonists. A subgroup analysis for patients with PSA [20 ng/ml resulted in cost savings of £1691 and a QALY gain of 0.45 per patient for degarelix versus 3-monthly goserelin. A subgroup analysis for patients with baseline CVD resulted in incremental costs of £6856, incremental QALYs of 1.63 and an incremental cost-effectiveness ratio (ICER) of £4216 per QALY gained for degarelix versus 3-monthly goserelin.
The CS presented a series of sensitivity analyses to test structural assumptions. The following assumptions had the greatest impact on the ICER: (1) if the efficacy of degarelix and LHRH agonists was assumed to be equal, the ICER for degarelix versus 3-monthly goserelin was estimated to be £12,987 per QALY gained; (2) if the HR for differential efficacy between degarelix and LHRH agonists was applied for 1 year (the duration for which comparative trial data exist), the ICER for degarelix versus 3-monthly goserelin was estimated to be £3751 per QALY gained; (3) if musculoskeletal AEs were excluded from the model, the ICER for degarelix versus 3-monthly goserelin was estimated to be £2484 per QALY gained; and (4) if abiraterone was excluded from the model, the ICER for degarelix versus 3-monthly goserelin was estimated to be £2072 per QALY gained.
Critique of the Cost-Effectiveness Evidence and Interpretation
The ERG considered the CS to be complete with regard to relevant published cost-effectiveness studies. The ERG also considered that the company's model adequately addressed the NICE reference case but noted that the economic evaluation had several significant limitations and that the CS did not contain an unbiased estimate of the technology's ICER. The limitations with the ICER estimates in relation to relevant populations, interventions, comparators and outcomes are discussed in turn below. Clinical advice received by the ERG suggested that treatment sequences vary between patients, so the 'treatment sequence' model structure used was inappropriate. The ERG considered that a model structure that explicitly modelled time to metastatic disease and time to death and allowed variation in treatment sequences would be more appropriate, flexible and transparent. The ERG noted that the company's assumption that treatment with degarelix or LHRH agonists would stop when chemotherapy was initiated did not universally reflect clinical practice and thus should not be used as a base-case assumption. The ERG also considered that, despite the paucity of evidence, subgroups could have been considered in exploratory analyses. For example, clinical advice suggested there may be considerable additional benefit in avoiding flare and associated AEs in the subgroups of 'patients with spinal metastases with impending or actual SCC' and 'patients with high tumour volume with impending or actual urinary outflow obstruction'.
The ERG considered that the company's model should have included all relevant trial data rather than relying on one single trial, CS21. The ERG considered that the company's scenario analyses around efficacy assumptions were appropriate and useful. The ERG also considered that the uncertainty surrounding HRQoL values was adequately represented by the scenario analyses included within the CS. The costs used within the economic model were clearly described, with the exception of the costs of treating SCC, which were not well reported.
The company's sensitivity analyses addressed many of the key areas of structural uncertainty within the model. The model used to undertake the company's probabilistic sensitivity analysis was not provided by the company as part of the original submission or the company's clarification response and thus could not be verified by the ERG. The model validation undertaken by the company was not comprehensive. In particular, the health professionals who were consulted by the company did not review the viability of the extrapolation of AE data beyond the observed period within the clinical trial.
Additional Work Undertaken by the ERG
The ERG undertook a revised NMA using informative priors for the heterogeneity parameter and the baseline treatment effect but non-informative priors for the treatment effects. The analyses showed that triptorelin was associated with lower mortality than leuprorelin (odds ratio [OR] 0.28; 95% credibility interval [CrI] 0.06-0.97). The ERG undertook an additional analysis taking into account the different study durations between the trials. These results were also in line with the OR results from the ERG's NMA.
The ERG undertook additional analyses including an ERG base-case analysis applying the following assumptions: (1) 3-monthly triptorelin was included as a comparator, (2) LHRH agonist treatment was assumed to be continued until death, (3) the HR for differential efficacy was applied for 1 year, (4) 70% of patients were assumed to receive chemotherapy after PSA progression, and (5) the proportion of patients receiving abiraterone was assumed to be 70%. The ERG's base case suggested that, compared with 3-monthly triptorelin, degarelix is associated with an additional cost of £3659 and produces an incremental QALY gain of 0.25: the corresponding ICER for degarelix versus 3-monthly triptorelin was estimated to be £14,798 per QALY gained.
The ERG's scenario analyses demonstrated that this ICER was very sensitive to four model assumptions: (1) the exclusion of SCC AEs from the analysis, (2) the modelling of fracture rates, (3) the assumption that PSA progression affects mortality rates in patients with metastases, and (4) the assumption of equal efficacy for degarelix and LHRH agonists. The ICERs obtained for degarelix versus 3-monthly triptorelin were £25,486 per QALY when SCC AEs were excluded from the analysis, £21,950 per QALY when fracture rates were assumed to be the same for both arms, £17,067 per QALY when no increased risk of mortality from PSA progression was applied, and £35,589 per QALY when the efficacy of degarelix and LHRH agonists was assumed to be equal. Finally, an ERG scenario analysis that explored the possible benefits of degarelix for the subgroup of 'patients with spinal metastases with actual or impending SCC' suggested degarelix had the potential to be cost saving.
Conclusions of the ERG Report
The decision problem addressed in the CS was relevant to the final NICE scope; however, the study populations were not fully reflective of the target population: men with advanced hormone-dependent prostate cancer. In addition, the frequency of flare protection was considerably lower in the trials than would be expected in clinical practice in England.
The key areas of uncertainty included the following:
1. The duration of the trials was inappropriate to determine OS benefits, and the data supporting the relationship between PSA progression and OS with degarelix were inconclusive.
2. LHRH agonists were considered to be equivalent in terms of efficacy and AEs without adequate justification. Efficacy and AEs for each LHRH agonist should have been modelled individually. 3. The claim of reduced cardiovascular AEs for degarelix compared with LHRH agonists was based on selective pooling of trial data. The analysis should have compared the fit of additional parametric curves, and the fit of the Weibull in the CS was poor for some AEs. 4. The data on PSA progression and AEs were for a maximum of 1 year in duration, so the company's model was based on extrapolation of these data, which introduces considerable uncertainty.
National Institute for Care and Excellence (NICE) Guidance
This section discusses some of the key issues considered by the Appraisal Committee in conjunction with advice from clinical experts and patient representatives. The full list of issues can be found in the FAD [3] .
Efficacy of Degarelix
The Committee noted that degarelix was non-inferior to LHRH agonists in suppressing testosterone levels and acknowledged that it was particularly beneficial for avoiding testosterone flare. The Committee heard from the clinical specialists and patient experts that degarelix was particularly beneficial for people with spinal metastases who are at risk of impending SCC. It also heard from the clinical specialists that not all patients with metastases were at risk of SCC, and the proportion of patients at risk was small. The Committee acknowledged that, although the proportion of patients at risk could be small, SCC is a serious and complex AE.
Uncertainties in the Evidence
The Committee considered that the results for PSA progression and long-term PSA progression benefit for degarelix compared with LHRH agonists were highly uncertain, and therefore no PSA progression benefit from degarelix compared with LHRH agonists could be assumed. The Committee also concluded that, whilst it was plausible to assume equivalent clinical efficacy between LHRH agonists, robust evidence to support an OS benefit for degarelix compared with LHRH agonists was lacking. Additionally, the Committee noted that because of the uncertainty around the company's pooled analyses, the data were not sufficiently robust to confirm that degarelix would reduce the risk of cardiovascular events in men with preexisting CVD compared with LHRH agonists. The Committee noted that the company did not present any data on SCC because it did not occur in the included trials. The Committee acknowledged that there was a known relationship between testosterone suppression, no risk of surge and flare and prevention of SCC. Therefore, it concluded that degarelix may offer potential benefit compared with LHRH agonists for people with spinal metastases who are at risk of impending SCC.
The Committee discussed the cost-effectiveness results produced using the company's model. It noted that the results were based on a deterministic estimate of the ICER and that the company did not provide a probabilistic estimate of the ICER. The Committee noted that degarelix dominated goserelin in the company's base-case analysis. It noted these results were based on assumptions of greater clinical efficacy in terms of PSA progression, OS and reductions in rates of fracture and of cardiovascular events for degarelix compared with LHRH agonists. It noted its earlier conclusions that the evidence informing these assumptions was considered to be subject to a high degree of uncertainty. The Committee concluded that the company's base-case ICER was based on assumptions that were not plausible and was likely to overestimate the cost effectiveness of degarelix compared with LHRH agonists.
The Committee noted that, on the basis of the assumptions used in the ERG's exploratory analyses, the ICERs for degarelix versus LHRH agonists were at least £35,600 per QALY gained compared with 3-monthly triptorelin, £28,000 per QALY gained compared with 3-monthly goserelin, and £26,200 per QALY gained compared with monthly leuprorelin. It noted that the ICER for degarelix versus triptorelin was £103,200 per QALY gained when its preferred assumption of no differences in the rates of fractures and cardiovascular AEs between degarelix and the LHRH agonists was applied. The Committee noted that all ICERs were outside the range normally considered a cost-effective use of NHS resources and concluded that degarelix could not be recommended for treating advanced hormone-dependent prostate cancer compared with LHRH agonists.
The Committee considered the ERG's exploratory analyses for people with spinal metastases with actual or impending SCC, which assumed that people receiving degarelix would not have SCC and that the efficacy of degarelix and LHRH agonists in terms of PSA progression and OS was equivalent. The Committee was persuaded that, on the basis of the ERG's analyses, degarelix could dominate triptorelin if the rate of SCC in this subgroup was higher than 3.5%. If the rate of SCC was lower than 3.5%, degarelix could still be cost effective compared with triptorelin. On balance, the Committee concluded that, on the basis of comments from the clinical specialists and patient experts, who noted that degarelix provided an important benefit for people with spinal metastases who are at risk of impending SCC for which no treatments are available, and the ERG's exploratory analysis, degarelix was a cost-effective use of NHS resources and could be recommended as an option for treating advanced hormone-dependent prostate cancer only for people with spinal metastases who are at risk of impending SCC.
Outcome of the Appraisal Committee Meeting
In November 2013, on the basis of the evidence available (including verbal testimony from invited clinical experts and patient representatives), the Appraisal Committee produced preliminary advice that degarelix was recommended only for patients ''at risk of impending SCC.'' However, in the NICE FAD, the wording of the recommendation was for ''people with spinal metastases who present with signs or symptoms of SCC.'' The company, together with patient groups, appealed this decision on the basis that the change in wording from the ACD to the FAD would substantially restrict and reduce the patient group that would be eligible to receive degarelix. The appeal was upheld on two points: first, NICE failed to issue a second ACD following a substantial change to the preliminary recommendations that significantly reduced the number of eligible patients who could be treated with degarelix and, second, the decision in the FAD to restrict use of degarelix to patients with spinal metastases who have actual SCC (as opposed to those who are ''at risk'' of SCC) lacked transparency and failed to give adequate reasons.
Following the appeal, NICE commissioned additional work from members of the ERG under the auspices of the NICE Decision Support Unit (DSU). The DSU carried out a rapid systematic review and economic assessment with the following objectives:
• To identify any relevant information on the rate of SCC in men with metastatic hormone-dependent prostate cancer or, if possible, those with spinal metastases.
• To explore the possibility of undertaking a subgroup analysis in men with spinal metastases and to perform an economic analysis if data were available with which to do so.
The DSU systematic review [16] found very limited evidence to assess the rate of SCC in the early stages of treatment with LHRH agonists or degarelix. The largest study located reported a rate of 0.96% for SCC occurring within the first 30 days of LHRH agonist therapy in men with metastatic disease [17] . Economic analyses using the Committee's preferred assumptions suggested that degarelix was not cost effective for the subgroup with metastatic disease. While degarelix could be cost effective for the subgroup with spinal metastases, data on the size of this subgroup and the rate of SCC were insufficient to estimate an ICER.
On 5 June 2015, NICE released a second ACD (ACD2) stating that ''degarelix is not recommended for treating advanced hormone-dependent prostate cancer.'' The company submitted a response to the ACD2 on 26 June 2015 and submitted additional information in September 2015 in response to a request for clarification from NICE. This response proposed the development of a clinically derived and workable definition for the subgroup suitable for treatment with degarelix. The company also provided a further review of the cost effectiveness of GnRH antagonists over agonists in the subgroup, taking into account the cost benefit of rapid symptom relief on hospital stay and a revised pricing policy aimed at reducing the acquisition cost of degarelix to enhance the cost effectiveness in the defined populations. The response included statements of support from Prostate Cancer UK, the British Association of Urological Surgeons (BAUS) and the British Uro-oncology Group (BUG) and a Delphi consultation summary conducted at the BAUS annual meeting in June 2015 about the specific patient populations that would be most suitable for treatment with degarelix.
NICE asked the ERG to review the company's response to the ACD2. The ERG's key points noted the following:
• There was a likelihood that the clinicians who participated in the Delphi exercise were predisposed to favour wider use of degarelix.
• The subgroup of patients suitable for treatment with degarelix resulting from the Delphi study included a number of vague definitions, e.g. systemic signs of cancer.
• No evidence was presented in the company's response to the ACD to substantiate the treatment delay associated with use of LHRH agonists or to support the claim of an increased risk of complications.
• The evidence supporting the size of the subgroup proposed in the company's response to the ACD was associated with uncertainty.
• The evidence supporting the number of days of hospitalisation was not well described and hence associated with uncertainty.
• The subgroup modelled in the new economic analysis was unclear, and the economic model was not suitably parameterised for undertaking subgroup analyses.
Outcome of the 5th Appraisal Committee Meeting
Following this process, the NICE recommendation was amended and the updated FAD stated, ''Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases, only if the commissioner can achieve at least the same discounted drug cost as that available to the NHS in June 2016 [3] .''
Key Methodological Issues
A key methodological issue during this STA concerned subgroup definition, particularly difficulty in defining a higher risk subgroup who may receive increased benefit from degarelix compared with the target population in the scope. For example, the subgroup of patients suitable for treatment with degarelix resulting from the Delphi study included a number of vague definitions, such as 'systemic signs of cancer'. Second, the economic model was not suitably parameterised for undertaking subgroup analyses. A main driver in cost effectiveness was the avoidance of SCC events. However, evidence on the risk of such events across different subgroups was limited and highly uncertain because of the rarity of such events. This STA illustrated the importance of having a complete understanding of the cost and occurrences of AEs when such events are pivotal to cost-effectiveness estimates.
The work described in the DSU report included analyses relating to the subgroups metastatic disease and spinal metastases; however, economic model inputs and assumptions related to the scope population rather than to the subgroups, so such analyses should be treated with caution.
Conclusion
NICE provided a positive recommendation for Degarelix only for a specific subgroup of those with spinal metastases from the initial target population of people with advanced hormone-dependent prostate cancer and dependent on discounted drug cost available to the NHS in June 2016. The NICE recommendations for research [18] also stated, ''further research is recommended to resolve uncertainties about the clinical effectiveness of degarelix compared with LHRH agonists such as leuprorelin, goserelin and triptorelin for treating advanced hormone-dependent prostate cancer, particularly in subgroups of people with pre-existing cardiovascular disease, people with skeletal (including spinal) metastases and people with impending ureteric and urethral obstruction. Research should be planned as part of well-conducted randomised clinical trials.''
